Is Roivant Sciences Ltd. (ROIV) a Buy, Sell, or Hold?
Roivant Sciences Ltd.
NASDAQ:ROIV
$34.89 USD
-$0.02 (-0.06%)
- Volume
- 2.47M
- Average Volume
- 6.06M
- Market Capitalization
- $25.1B
- P/E Ratio
- -77.53
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $37.00
- Year Low
- $10.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.37
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Matthew Gline |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ROIV |
| CUSIP | G76279101 |
| CIK | 0001635088 |
| Web | https://roivant.com |
| Phone | 44 2074 003 347 |
| Currency | USD |
| Employees | 721 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 18.37 |
| Quick Ratio | 18.37 |
| Cash Ratio | 5.06 |
Sales & Book Value
| Annual Sales | $8.26M |
| Price / Sales | 3038.18 |
| Cash Flow | -1.08 |
| Price / Cash Flow | -33.08 |
| Price / Book | 5.41 |
Price Target and Rating
| Average Stock Price Forecast | $38.00 |
| High Stock Price Forecast | $42.00 |
| Low Stock Price Forecast | $30.00 |
| Forecast Upside/Downside | -8.18% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.43 |
| Trailing P/E Ratio | -77.53 |
| PEG Ratio | 0.92 |
| P/E Growth | 0.92 |
| Net Income | $-299.77M |
| Net Margin | -3629.19% |
| Pretax Margin | -3203.12% |
| Return on Equity | -6.85% |
| Return on Assets | -5.23% |
Financials Score
| AltmanZ Score | 35.38 |
| Piotroski Score | 1.00 |
| Working Capital | 4.89B |
| Total Assets | 5.73B |
| Ebit | -264.58M |
| Market Cap | 25.14B |
| Total Liabilities | 435.63M |
Poll Results
About Roivant Sciences Ltd. (NASDAQ:ROIV) Stock
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom. ...
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
2026-07-07 06:15:00
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib. The stock is arguably expensive now, even with aggressive revenue estimates for 2031.
2026-06-09 20:22:12
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-03 18:32:01
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-05-29 17:24:06
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
2026-05-21 13:09:35
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
2026-05-20 18:20:55
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Q4 Earnings Call Highlights
2026-05-20 10:08:42
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
2026-05-20 09:15:12
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
Frequently Asked Questions
-
What is the current Roivant Sciences Ltd. (ROIV) stock price?
-
Roivant Sciences Ltd.(NASDAQ:ROIV) stock price is $34.89 in the last trading session. During the trading session, ROIV stock reached the peak price of $37 while $10.9 was the lowest point it dropped to. The percentage change in ROIV stock occurred in the recent session was --0.06% while the dollar amount for the price change in ROIV stock was -$-0.02.
-
ROIV's industry and sector of operation?
-
The NASDAQ listed ROIV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ROIV?
-
Frank Torti | President & Vant Chair
Huafeng Xu | Chief Technology Officer
Alex Gasner | Executive Vice President of Roivant Health
Ian Rosenblum | Chief Information Officer
Josh Chen | General Counsel -
How many employees does ROIV have?
-
Number of ROIV employees currently stands at 721. ROIV operates from 11-12 St. James's Square, London, GL SW1Y 4LB, GB.
-
Link for ROIV official website?
-
Official Website of ROIV is: https://roivant.com
-
How do I contact ROIV?
-
ROIV could be contacted at phone #44 2074 003 347 and can also be accessed through its website. ROIV operates from 11-12 St. James's Square, London, GL SW1Y 4LB, GB.
-
How many shares of ROIV are traded daily?
-
The average number of ROIV shares traded daily for last 3 months was 6.06M.
-
What is the market cap of ROIV currently?
-
The market value of ROIV currently stands at $25.1B with its latest stock price at $34.89